Form 4: Immunome Inc. Executive Acquires Stock Options
SEC Form 4 Filing
Kinney Horn, Chief Business Officer of Immunome Inc., acquired stock options for 130,000 shares on August 9, 2024.
Summary
- Kinney Horn, the Chief Business Officer of Immunome Inc., filed a Form 4 on August 13, 2024.
- The filing reports a transaction that occurred on August 9, 2024, where Horn acquired stock options for 130,000 shares of Immunome Inc. common stock.
- The exercise price of the stock options is $12.92.
- The options vest over time, with 25% vesting on August 9, 2025, and the remaining shares vesting monthly over the following three years.
- The options expire on August 8, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own. The vesting schedule suggests a long-term commitment from the executive.
Positives
- The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of executive compensation and are common in the biotechnology industry. They provide transparency into the holdings and transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of the stock option acquisition. |
| 08/09/2025 | Date when 25% of the stock options vest. |
| 08/08/2034 | Expiration date of the stock options. |
| 08/13/2024 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.